Clinical Characteristics and Degree of Glycemic and Cardiovascular Risk Factor Control in Patients with Type 1 Diabetes in Catalonia (Spain).
cardiovascular risk factors
complications
glucose control
type-1 diabetes
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Apr 2021
06 Apr 2021
Historique:
received:
31
01
2021
revised:
19
03
2021
accepted:
26
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
This study aims to evaluate the clinical characteristics, complications, degree of glycemic control, and cardiovascular risk factor control in patients with type 1 diabetes in Catalonia (Northwest of Spain). Cross-sectional study using a database including clinical, laboratory, and treatment data. Patients with an ICD10 diagnosis of type 1 diabetes were included, excluding those treated with glucose-lowering agents other than insulin, or treated only with basal insulin two years after diagnosis. 15,008 patients were analysed. Median IQR age was 42 (31-53) years, diabetes duration 11.8 (6.8-16.0) years, 56.5% men. Median (IQR) HbA1c was 7.9% (7.1-8.8). Microvascular complications were present in 24.4% of patients, 43.6% in those with a diabetes duration >19 years. In presence of known cardiovascular disease 69.3% of patients showed an LDL-C concentration >70 mg/dL, 37% had a systolic blood pressure >135 mmHg and 22.4% were smokers. This study provides a reliable snapshot about the clinical situation of a large population of patients with T1D in Catalonia, which is similar to that of other western areas. The lack of adequate control of cardiovascular risk factors in a significant proportion of patients with cardiovascular disease deserves a more detailed analysis and urges the need for improvement strategies.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to evaluate the clinical characteristics, complications, degree of glycemic control, and cardiovascular risk factor control in patients with type 1 diabetes in Catalonia (Northwest of Spain).
METHODS
METHODS
Cross-sectional study using a database including clinical, laboratory, and treatment data. Patients with an ICD10 diagnosis of type 1 diabetes were included, excluding those treated with glucose-lowering agents other than insulin, or treated only with basal insulin two years after diagnosis.
RESULTS
RESULTS
15,008 patients were analysed. Median IQR age was 42 (31-53) years, diabetes duration 11.8 (6.8-16.0) years, 56.5% men. Median (IQR) HbA1c was 7.9% (7.1-8.8). Microvascular complications were present in 24.4% of patients, 43.6% in those with a diabetes duration >19 years. In presence of known cardiovascular disease 69.3% of patients showed an LDL-C concentration >70 mg/dL, 37% had a systolic blood pressure >135 mmHg and 22.4% were smokers.
CONCLUSIONS
CONCLUSIONS
This study provides a reliable snapshot about the clinical situation of a large population of patients with T1D in Catalonia, which is similar to that of other western areas. The lack of adequate control of cardiovascular risk factors in a significant proportion of patients with cardiovascular disease deserves a more detailed analysis and urges the need for improvement strategies.
Identifiants
pubmed: 33917523
pii: jcm10071536
doi: 10.3390/jcm10071536
pmc: PMC8038775
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Lilly S.A. Spain
ID : NA
Références
Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122
pubmed: 24526393
N Engl J Med. 2005 Dec 22;353(25):2643-53
pubmed: 16371630
Ther Adv Endocrinol Metab. 2019 Feb 28;10:2042018819830867
pubmed: 30834104
Diabetes. 2019 Feb;68(2):409-419
pubmed: 30409781
BMJ Open. 2017 Feb 28;7(2):e014444
pubmed: 28246144
Diabetes Res Clin Pract. 2016 Jan;111:51-7
pubmed: 26597211
Diabetes Res Clin Pract. 2019 Nov;157:107842
pubmed: 31518658
Eur Heart J. 2018 Apr 7;39(14):1172-1180
pubmed: 29069377
Circulation. 2016 Mar 15;133(11):1058-66
pubmed: 26888765
Diabetes Care. 2012 Apr;35(4):774-9
pubmed: 22344609
Med Clin (Barc). 2009 Apr 4;132(12):454-8
pubmed: 19303112
Diabet Med. 2012 Feb;29(2):181-9
pubmed: 21883428
Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123
pubmed: 30559236
Endocrinol Nutr. 2016 Apr;63(4):157-63
pubmed: 26948542
Diabetes Care. 2019 May;42(5):875-882
pubmed: 30833368
Diabetes Obes Metab. 2018 Aug;20(8):1965-1971
pubmed: 29687581
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70
pubmed: 30559232
BMJ Open. 2016 Oct 5;6(10):e012463
pubmed: 27707830
Diabetes Res Clin Pract. 2019 May;151:224-230
pubmed: 31004670
PLoS One. 2016 Nov 3;11(11):e0164977
pubmed: 27812145
Pediatr Diabetes. 2007 Dec;8(6):369-73
pubmed: 18036062
Diabetes Res Clin Pract. 2016 May;115:9-16
pubmed: 27242117
Diabetes Care. 2014 Oct;37(10):2843-63
pubmed: 25114297
Lancet. 2018 Aug 11;392(10146):477-486
pubmed: 30129464
Diabetes Obes Metab. 2006 Nov;8(6):682-9
pubmed: 17026493
J Intern Med. 2017 Mar;281(3):261-272
pubmed: 27925333
Diabetes Care. 1996 Jul;19(7):689-97
pubmed: 8799621
PLoS One. 2017 Mar 31;12(3):e0174979
pubmed: 28362881
Circulation. 2019 Apr 16;139(16):1900-1912
pubmed: 30798638
Diabetes Care. 2019 Dec;42(12):2220-2227
pubmed: 31548241
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
Diabetes Obes Metab. 2020 Apr;22(4):622-630
pubmed: 31789439
Diabetologia. 1992 Mar;35(3):267-71
pubmed: 1563583
Atherosclerosis. 2019 Nov;290:140-205
pubmed: 31591002